Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
Instituto Nacional de Medicamentos (INAME), Departamento de Farmacología, Av. Caseros 2161 (1264), Buenos Aires, Argentina.
Environ Toxicol Pharmacol. 2012 Sep;34(2):223-227. doi: 10.1016/j.etap.2012.04.004. Epub 2012 Apr 10.
The aim of this research has been to determine the biperiden hydrochloride permeability in Caco-2 model, in order to classify it based on the Biopharmaceutics Classification System (BCS). The World Health Organization (WHO) as well as many other authors have provisionally assigned the drug as BCS class I (high solubility-high permeability) or III (high solubility-low permeability), based on different methods. We determined biperiden BCS class by comparing its permeability to 5 pre-defined compounds: atenolol and ranitidine hydrochloride (low permeability group) and metoprolol tartrate, sodium naproxen and theophylline (high permeability group). Since biperiden permeability was higher than those obtained for high permeability drugs, we classified it as a BCS class I compound. On the other hand, as no differences were obtained for permeability values when apical to basolateral and basolateral to apical fluxes were studied, this drug cannot act as a substrate of efflux transporters. As a consequence of our results, we suggest that the widely used antiparkinsonian drug, biperiden, should be candidate for a waiver of in vivo bioequivalence studies.
本研究旨在测定盐酸比哌立登在 Caco-2 模型中的渗透性,以便根据生物药剂学分类系统(BCS)对其进行分类。世界卫生组织(WHO)以及许多其他作者已经根据不同的方法将该药物临时归类为 BCS 类别 I(高溶解度-高渗透性)或 III(高溶解度-低渗透性)。我们通过将其渗透性与 5 种预先定义的化合物进行比较来确定比哌立登的 BCS 类别:阿替洛尔和盐酸雷尼替丁(低渗透性组)和酒石酸美托洛尔、萘普生钠和茶碱(高渗透性组)。由于比哌立登的渗透性高于高渗透性药物的渗透性,因此将其归类为 BCS 类别 I 化合物。另一方面,由于在研究顶侧到基底侧和基底侧到顶侧通量时没有获得渗透性值的差异,因此该药物不能作为外排转运体的底物。根据我们的结果,我们建议广泛使用的抗帕金森病药物比哌立登应成为豁免体内生物等效性研究的候选药物。